10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-CDC34/Ubch3 Rabbit Monoclonal Antibody

Catalog # ABO13715

Product Information

Application	WB, IF, ICC, IP, FC
Primary Accession	P49427
Host	Rabbit
Isotype	Rabbit IgG
Reactivity	Rat, Human, Mouse
Clonality	Monoclonal
Format	Liquid
Description	Anti-CDC34/Ubch3 Rabbit Monoclonal Antibody . Tested in WB, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.

Additional Information

Gene ID	997
Other Names	Ubiquitin-conjugating enzyme E2 R1, 2.3.2.23, (E3-independent) E2 ubiquitin-conjugating enzyme R1, 2.3.2.24, E2 ubiquitin-conjugating enzyme R1, Ubiquitin-conjugating enzyme E2-32 kDa complementing, Ubiquitin-conjugating enzyme E2-CDC34, Ubiquitin-protein ligase R1, CDC34, UBCH3, UBE2R1
Calculated MW	26737
Application Details	WB 1:500-1:2000 ICC/IF 1:50-1:200 IP 1:50 FC 1:50
Subcellular Localization	Cytoplasm. Nucleus. The phosphorylation of the C-terminal tail plays an important role in mediating nuclear localization. Colocalizes with beta-tubulin on mitotic spindles in anaphase.
Tissue Specificity	Expressed in testes during spermatogenesis to regulate repression of cAMP-induced transcription..
Source	Eukaryota
Contents	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.
Clone Names	Clone: IBO-3
Immunogen	A synthesized peptide derived from human CDC34
Purification	Affinity-chromatography

Storage	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.

Protein Information

Name	CDC34
Synonyms	UBCH3, UBE2R1
Function	E2 ubiquitin-conjugating enzyme that accepts ubiquitin from an E1 ubiquitin-activating protein, and catalyzes its covalent attachment to other proteins by an E3 ubiquitin-protein ligase complex (PubMed:10329681, PubMed:17588522, PubMed:20061386, PubMed:38326650). In vitro catalyzes 'Lys-48'-linked polyubiquitination (PubMed:22496338). Cooperates with the E2 UBCH5C and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation (PubMed:10329681, PubMed:10918611, PubMed:17698585). Performs ubiquitin chain elongation building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. UBE2D3 acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin. Cooperates with the SCF(SKP2) E3 ligase complex to regulate cell proliferation through ubiquitination and degradation of MYBL2 and KIP1 (PubMed:10871850, PubMed:15652359, PubMed:19112177). Involved in ubiquitin conjugation and degradation of CREM isoform ICERIIgamma and ATF15 resulting in abrogation of ICERIIgamma- and ATF5-mediated repression of cAMP-induced transcription during both meiotic and mitotic cell cycles. Involved in the regulation of the cell cycle G2/M phase through its targeting of the WEE1 kinase for ubiquitination and degradation (PubMed:19126550). Also involved in the degradation of beta-catenin (PubMed:12037680). Is target of human herpes virus 1 protein ICP0, leading to ICP0-dependent dynamic interaction with proteasomes (PubMed:11805320, PubMed:12060736).
Cellular Location	Cytoplasm. Nucleus. Note=The phosphorylation of the C-terminal tail plays an important role in mediating nuclear localization. Colocalizes with beta-tubulin on mitotic spindles in anaphase
Tissue Location	Expressed in testes during spermatogenesis to regulate repression of cAMP-induced transcription

Images



All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.

All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.





All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.



Western blot analysis of CDC34 expression in (1) Jurkat cell lysate; (2) NIH/3T3 cell lysate.



Immunofluorescent analysis of Hela cells, using CDC34 Antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.